Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

NIRMATRELVIR AND RI

Active
SPE2DP-26-T-4361Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract specifies the procurement of PAXLOVID, a combination antiviral medication containing nirmatrelvir and ritonavir, supplied in blister cards with each card containing two 150 mg nirmatrelvir tablets and one 100 mg ritonavir tablet, representing a single daily dose. Each box contains ten blister cards, providing a full five-day treatment course with two doses per day. The product is manufactured by Pfizer Inc under part number NDC00069-5321-30 and is regulated by the FDA. The item has a fixed shelf life of 36 months, non-extendable, and must be packaged in compliance with DLA standards including MIL-STD-2073-1E and Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must ensure protection from damage and use commercial-grade containers suitable for safe transport at the lowest carrier rate. Each shipment must be palletized per DLA requirements and marked with specific identifiers, and delivery is required FOB destination to the Navy Expeditionary Central Facility in Williamsburg, Virginia. The order quantity is 50 boxes, with a strict 20-day delivery window from the award date, and zero tolerance for quantity variance. Shipment must occur via the fastest traceable means, explicitly excluding parcel post, and must be delivered no later than April 28, 2026. Bidders must specify the manufacturer, part number, and source, and the contracting officer must refer the bid to a product specialist for FDA-regulated product confirmation.

General Info

Procure 50 boxes of PAXLOVID, FDA-regulated, 5-day course, FOB Williamsburg VA, deliver by April 28, 2026.

Agency

Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSAView Agency

NAICS

325411 - Medicinal and Botanical ManufacturingView NAICS

Place of Performance

BLDG 4 D STREET, WILLIAMSBURG, VA, 23185, US

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA
View Agency Profile
Office AddressUS
Contacts

Full Description

Show more
NIRMATRELVIR AND RI
NIRMATRELVIR AND RITONAVIR TABLETS
PAXLOVIDNIRMATRELVIR 300 GM RITONAVIR
100 MG. 10 BLISTER CARDS. EACH BLISTER
CARD CONTAINS 3 TABLETS: 2 NIRMATRELVIR
TABLETS (150 MG EACH) 1 RITONAVIR TABLET
(100 MG EACH). EACH BLISTER CARD CONTAINS
ONE DOSE (MUST TAKE ALL THREE TABLETS).
BOX CONTAINS 5 DAY SUPPLY OF TWO DAILY DOSES.
.
RS020: Shelf-life requirement RS001 for a TYPE I (CODE Q) item with a shelf life of 36 months (non-extendable) applies to this item.
. UNIT OF ISSUE BOX OF 10 EA . RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS (IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB AT:
http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx
FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS.
RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES
.
BIDDER SHALL SPECIFY SOURCE AND
PART NUMBER BEING SUPPLIED.
.
This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description. .
PFIZER INC 86491 P/N NDC00069-5321-30
DLA issues this document using the DoD authorized unit of issue, please refer to the following URL to determine the corresponding ANSI X12 unit of issue.
https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.dla.mil%2FPortals%2F104%2FDocuments% 2FDLMS%2FeApplications%2FLogDataAdmin%2FUnitofIssueandPurchaseUnit.xlsx&wdOrigin=BROWSELINK
CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE.
0001 7017575510 0001 BX 50.000
SPE2DP-26-T-4361
SECTION B
PR: 7017575510 PRLI: 0001 CONT’D
NSN/MATERIAL:6505017227590
DELIVERY (IN DAYS):0020
DELIVER FOB: DESTINATION
QTY VARIANCE: PLUS 0% MINUS 0%
INSPECTION POINT: DESTINATION
ACCEPTANCE POINT: DESTINATION
PREP FOR DELIVERY:
PKGING DATA MIL-STD-2073-1E
QUP:001 PRES MTHD:ZZ CLNG/DRY:Z PRESV MAT:ZZ
WRAP MAT:ZZ CUSH/DUNN MAT:ZZ CUSH/DUNN THKNESS:Z
UNIT CONT:ZZ OPI:M
INTRMDTE CONT:ZZ INTRMDTE CONT QTY:ZZZ
PACK CODE:U
MARKING SHALL BE IN ACCORDANCE WITH MIL-STD-129.
SPECIAL MARKING CODE:ZZ -ZZ Special Requirements
PALLETIZATION SHALL BE IN ACCORDANCE WITH RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT
APPLICABLE TO ALL MEDICAL ACQUISITIONS:
PACKAGING AND PACKING SHALL BE COMMERCIAL AS
SPECIFIED IN THE PROCUREMENT DOCUMENT.
EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED
IN A SUITABLE SEALED UNIT CONTAINER CAPABLE
OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR
BREAKAGE.
UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL
EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN
NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND
SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT
THE LOWEST RATE, TO POINT OF DELIVERY CALLED
FOR IN THE CONTRACT OR ORDER.
MATERIAL MUST BE MARKED IAW MEDICAL MARKING
STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES
TO MIL-STD-129.
COPIES OF MEDICAL MARKING STANDARD NO. 1
(MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA
TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/
PARCEL POST ADDRESS:
V4582F
NAVY EXPEDITIONARY CENTRAL FACILITY
CENTRAL ISSUE FACILITY
BLDG 4 D STREET
WILLIAMSBURG VA 23185
US
SPE2DP-26-T-4361
SECTION B
PR: 7017575510 PRLI: 0001 CONT’D
VESSEL SHIPMENT. TRANSPORTATION SEE DLAD PROC NOTE C19. FIRST DESTINATION TRANSPORTATION SEE DLAD PROC
NOTE C20 AND CONTRACT
FREIGHT SHIPPING ADDRESS:
V4582F
NAVY EXPEDITIONARY CENTRAL FACILITY
CENTRAL ISSUE FACILITY
BLDG 4 D STREET
WILLIAMSBURG VA 23185
US
RDD 777 SHIPMENT. SHIP BY FASTEST TRACEABLE MEANS. DO NOT USE PARCEL POST.
M/F: (TCN) V4582F6110M023
RDD: 777
PROJ: LP5 TP 2
SUPP ADD: SIG: A
FOR GOVERNMENT USE ONLY: (IPD) 06
DIC: A4A DIST: 9B ADV: 2A FC: P7
Need Ship Date:00/00/0000 Original Required Delivery Date:04/28/2026
SPE2DP-26-T-4361 NSN/Part Number: 6505-01-722-7590 Quantity: 50 BX Purchase Request: 7017575510QTY: 50 Delivery: 20 days ADO

Similar Contracts

Same NAICS industry code

NAICS: 325411
New
DIBBS
PHENYLEPHRINE HYDRO
Solicitation # SPE2DP-26-T-4342
The contract specifies the procurement of Phenylephrine Hydrochloride Ophthalmic Solution USP 2.5% in 10 mL sterile, aqueous, topical bottles manufactured by Bausch & Lomb Americas Inc. with NDC 82260-0102-10, to be delivered in a quantity of six bottles under solicitation SPE2DP-26-T-4342. The product must be stored at 2°C to 25°C (36°F to 77°F) and packaged in sealed unit containers that protect against damage, with all outer shipping containers meeting commercial standards for safe transport by common carrier at the lowest cost to the designated destination in Williamsburg, VA. Packaging and marking must comply with Medical Marking Standard No. 1, replacing all references to MIL-STD-129, and palletization must follow DLA Packaging Requirements for Procurement. The item has a non-extendable shelf life of 24 months as a TYPE I (CODE M) product and must be labeled accordingly. The solution is contained in opaque white LDPE bottles with LLDPE dropper tips and red caps, and the entire shipment must be delivered FOB destination within five days of the order. Shipment must be sent by the fastest traceable means; parcel post is prohibited. Delivery is required by April 15, 2026, with inspection and acceptance occurring at the destination point. The National Stock Number is 6505017090360 and the purchase request number is 7016297029. The item is regulated by the FDA, requiring a referral to the product specialist through EBS with full bidder and manufacturer details. All technical and quality requirements are governed by the DLA Master List of Technical and Quality Requirements, with the revision in effect on the solicitation issue date controlling. Contract-specific identifiers, including CLIN, pricing, and unit of issue, are structured under the DoD authorized unit of issue system, and all documentation must reflect current DLA standards for marking, packaging, and logistics. The point of contact for inquiries is James Mariani of the Department of Defense Medical Supply Chain.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

2 days ago

DEADLINE

in 4 days
View Details
NAICS: 325411
New
DIBBS
DIETARY SUPPLEMENT, THE
Solicitation # SPE2DP-26-Q-0125
The contract specifies the procurement of an unflavored therapeutic dietary supplement in powder form, with each package containing six individual packets, each yielding 8 to 10 ounces of liquid when reconstituted. The product is lactose-free and must have a shelf life of 18 months, with no more than three months elapsed between manufacture and delivery to the government. Each package must be sealed in a unit container that protects the contents from damage and packed in commercial shipping containers suitable for safe transport at the lowest cost to the delivery point. All packaging and labeling must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and must adhere to DLA’s Master List of Technical and Quality Requirements, which take precedence over ASTM D3951. Palatalization must follow DLA Packaging Requirements for Procurement. The unit of issue is the package, with four packages required, delivered in two separate shipments to two distinct government addresses—one in Perry Point, Maryland, and another in San Antonio, Texas—by traceable freight means only, prohibiting parcel post. Delivery is required within 35 days after order date, with inspection and acceptance occurring at the destination. Pricing is firm fixed, with no variance allowed in quantity. The supplier must comply with federal clauses related to veteran employment reports, sustainable products, and wide area workflow payment. The item’s NSN is 8940-01-317-9838, and the solicitation number is SPE2DP-26-Q-0125.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

2 days ago

DEADLINE

in 6 days
View Details
NAICS: 325411
New
Federal
Surge-Capable Domestic BiomanufacturingThe contract seeks to establish large-scale domestic manufacturing of dermal substitutes in the United States with built-in surge capacity to support mass casualty and emergency response scenarios. The effort is focused on creating a resilient, onshore production capability capable of rapidly scaling output during public health emergencies, ensuring timely availability of critical wound care products when demand spikes. This initiative is aligned with national preparedness goals and underscores a strategic push to reduce reliance on overseas supply chains for life-saving medical materials. The award is structured as a subcontract under the Administration for Strategic Preparedness and Response within the Department of Health and Human Services, with a North American Industry Classification System code of 325411 for pharmaceutical and medicine manufacturing. The solicitation was posted on July 28, 2026, and responses are due by August 28, 2026. Although the place of performance is listed with a zip code of 77416, no specific city or state is provided, and no point of contact details are included. The contract does not specify a set-aside status, indicating it is open to all qualified entities regardless of size or ownership. The focus remains on achieving domestic production capacity that can maintain steady output and immediately ramp up during crises.
Aspr Administration For Strategic Preparedness And Response

POSTED

2 days ago

DEADLINE

in 29 days
View Details
NAICS: 325411
New
DIBBS
TRANEXAMIC ACID INJECT
Solicitation # SPE2DP-26-T-4321
Tranexamic acid injection is a sterile, single-dose, unpreserved intravenous solution containing 10 mg of tranexamic acid USP per mL, formulated in 100 mL with 7 mg of sodium chloride USP in water for injection USP, with a pH range of 6.5 to 8.0. Each unit is supplied in a polymer bag sealed with a twist-off port and oversealed in an aluminum pouch, containing a total of 1000 mg of tranexamic acid. The product must be stored at 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C and 30°C (59°F to 86°F), and has a non-extendable shelf life of 24 months. Each case contains ten single-dose bags, and the item is identified by NSN 6505-01-694-2815 and NDC 51754-0108-03, manufactured by EXELA PHARMA SCIENCES LLC. Packaging and marking must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, and must meet DLA packaging requirements for procurement, including palletization and protective measures to ensure safe transport. The contract specifies delivery to Fort Bragg, NC, within 20 days of award, with FOB destination terms, zero quantity variance, and inspection and acceptance occurring at the delivery point. The item is subject to defense information coverage requirements and must be shipped via traceable means, excluding parcel post. The solicitation number is SPE2DP-26-T-4321, with a response deadline of August 3, 2026, and the original required delivery date is July 29, 2026.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

3 days ago

DEADLINE

in 4 days
View Details

More opportunities from Department Of Defense → MEDICAL SUPPLY CHAIN PHARM FSA

Same awarding agency

NAICS: 325412
New
DIBBS
NORETHINDRONE AND E
Solicitation # SPE2DP-26-T-4362
The contract pertains to the procurement of 1 mg norethindrone and 0.035 mg ethinyl estradiol tablets in a 28-tablet cycle format, with six cycles per package totaling 168 tablets per unit, designated as a single package unit of issue. The product must comply with stringent technical and quality requirements outlined in the DLA Master List of Technical and Quality Requirements, including adherence to the Medical Marking Standard No. 1 dated February 4, 2013, which supersedes MIL-STD-129. Shelf life is strictly limited to 36 months with no extensions permitted, and storage must be maintained at 20–25°C (68–77°F) as per USP controlled room temperature standards. Labeling must include the NSN, manufacturer, CAGE code, date of manufacture, expiration date, contract number, and lot number. Packaging must be commercial-grade, sealed to prevent damage or breakage, and shipped in suitable exterior containers to ensure safe, cost-effective delivery to the destination point under FOB destination terms. The item is manufactured by Teva Pharmaceuticals USA, Inc., with NDC 00555-9010-58, and is identified by NSN 6505-01-365-2363. Delivery is required within 20 days, with zero tolerance for variance in quantity, and inspection and acceptance occur at the destination. The solicitation is issued under contract number SPE2DP-26-T-4362, with a response deadline of August 4, 2026, and is managed by the Department of Defense’s Medical Supply Chain Pharm FSA, with Timothy McCauley listed as the primary point of contact.
Pharmaceutical Preparation Manufacturing

POSTED

about 20 hours ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
MULTIPLE
Solicitation # SPE2DP-26-T-4366
The contract specifies the procurement of MULTIPLE ELECTROLYTES INJECTION, TYPE 1, USP, in 1000 mL plastic bags, containing 14 units per case, with a pharmaceutical pH of 7.4. The product is manufactured by BAXTER HEALTHCARE CORPORATION under part number 2B2544X and is regulated by the FDA. It must be stored at room temperature, 25°C (77°F), with avoidance of excessive heat, and kept tightly closed in a cool, well-ventilated environment. The item has a non-extendable shelf life of 18 months as governed by RS001 for TYPE I (CODE K) classification and must be marked in accordance with the latest Medical Marking Standard No. 1. Packaging must comply with MIL-STD-2073-1E and the DLA packaging requirements, with latex-free plastic containers. The NSN is 6505014625492, and the unit of issue is PG, with a single unit ordered. Delivery is required within 20 days FOB destination, with zero tolerance for quantity variance and inspection and acceptance occurring at the destination. The solicitation number is SPE2DP-26-T-4366, issued by the Department of Defense’s Medical Supply Chain PHARM FSA with performance at Fort Bragg, North Carolina. Technical and quality requirements referenced under R numbers are governed by the DLA Master List of Technical and Quality Requirements, with revision control tied to the solicitation issue date. The contracting official must submit an EBS referral for FDA-regulated product confirmation, including bidder and manufacturer details. The contract was posted July 29, 2026, with a response deadline of August 4, 2026, under NAICS code 325412 for pharmaceutical preparation manufacturing.
Pharmaceutical Preparation Manufacturing

POSTED

about 20 hours ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
ZINC OXIDE OINTMENT
Solicitation # SPE2DP-26-T-4364
The contract specifies the procurement of Zinc Oxide Ointment USP, a topical skin protectant containing 20% zinc oxide, supplied in collapsible tubes of 28.35 grams per unit, designated as a tube (TU). The product must be stored at controlled room temperature not exceeding 30°C (86°F) and has a non-extendable shelf life of 36 months as a Type I (Code Q) item. Packaging and labeling must strictly comply with MIL-STD-129 and the latest Medical Marking Standard No. 1, with all packaging requirements governed by the DLA Master List of Technical and Quality Requirements, which override ASTM D3951. The item is regulated by the FDA, requiring buyer referral for confirmation, and must be shipped via traceable means, excluding parcel post. All shipments are FOB destination with no quantity variance allowed, and inspection and acceptance occur at the delivery point. The item is identified by NSN 6505001501990 and manufacturer part number NDC67777-0223-11 from Dynarex Corp. Deliveries are split across six CLINs totaling 30 tubes, with delivery dates ranging from July 15 to July 30, 2026, directed to various military and government installations across the United States. Each delivery location has specific freight and marking instructions, including traceable carrier details and contract identifiers, and all must adhere to DLA packaging and palletization standards under RP001. The contract number is SPE2DP-26-T-4364 and the unit price is $3.00 per tube for all line items.
Pharmaceutical Preparation Manufacturing

POSTED

about 20 hours ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
BENZONATATE CAPSULES
Solicitation # SPE2DP-26-T-4357
BENZONATATE CAPSULES, USP, 100 MG, are supplied in bottles of 100 capsules each, with the active ingredient being 100 milligrams of benzonatate per capsule. The product must be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F) and protected from light, moisture, and humidity. This item falls under a Type I (Code Q) shelf-life classification with a non-extendable shelf life of 36 months and must be marked in accordance with the latest edition of Medical Marking Standard No. 1. It is regulated by the FDA, and buyers are required to submit a referral via EBS to the product specialist, including bidder and manufacturer details such as names, part numbers, and NDC codes. The item is subject to DLA packaging requirements and technical quality standards referenced in the DLA Master List of Technical and Quality Requirements. The contract specifies delivery of four bottles under purchase request 7017663196, with delivery due within 20 days FOB destination, no variance allowed in quantity, and inspection and acceptance occurring at the destination. The NSN is 6505-00-660-1798, and the solicitation number is SPE2DP-26-T-4357, issued by the Department of Defense’s Medical Supply Chain PHARM FSA, with a response deadline of August 4, 2026. Primary point of contact is Imerah Burnett, and packaging must comply with MIL-STD-2073-1E.
Pharmaceutical Preparation Manufacturing

POSTED

about 20 hours ago

DEADLINE

in 5 days
View Details
NAICS: 424210
New
DIBBS
BENZOIN TINCTURE, COMPO
Solicitation # SPE2DP-26-T-4356
Benzoin Tincture, Compound, USP is an over-the-counter topical product intended for external use only, containing 1000 mg of Benzoin Resin per milliliter as the active ingredient and 77 percent alcohol as an inactive ingredient. It is supplied in 16-ounce bottles, equivalent to one pint or 473 milliliters, and is classified as a flammable substance requiring storage between 20°C and 25°C in accordance with USP controlled room temperature standards. The item has a non-extendable shelf life of 36 months, and any delivery to the first government activity must ensure a minimum of 31 months of remaining shelf life at the time of receipt. This product is regulated by the FDA and is subject to hazardous materials requirements, including the mandatory inclusion of a current Material Safety Data Sheet (MSDS) with every shipment and electronic submission to DLA.MSDS@DLA.MIL using the required cover sheet P-75. Packaging must comply with 49 CFR and ICAO regulations for hazardous materials, and all items must be marked in accordance with Medical Marking Standard No. 1, superseding MIL-STD-129. The item is covered under Defense Information potentially applicable provisions and incorporates technical and quality requirements from the DLA Master List. It is identified by NSN 6505-01-654-9628 under solicitation SPE2DP-26-T-4356, with a 20-day delivery deadline and procurement through the Department of Defense’s Medical Supply Chain.
Drugs and Druggists' Sundries Merchant Wholesalers

POSTED

about 20 hours ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
TRICHLOROACETIC ACID
Solicitation # SPE2DP-26-T-4354
The contract specifies the procurement of Trichloroacetic Acid, ACS grade, 80% concentration, in 15 mL units, identified by NSN 6505-01-363-7674 and part number 749887 from AmerisourceBergen Drug Corp. The item is classified as a TYPE I (CODE M) with a non-extendable shelf life of 24 months and must be packaged and marked in full compliance with Medical Marking Standard No. 1, superseding MIL-STD-129. Packaging must meet commercial standards with sealed unit containers and shipping containers capable of preventing damage during transit, ensuring safe delivery by common carrier at the lowest cost to the designated destination in APO, 09094-3219. The item is regulated by the FDA, requiring referral through EBS for confirmation, and delivery must occur within 20 days FOB destination with zero quantity variance allowed. Inspection and acceptance occur at the delivery point. Suppliers must provide Safety Data Sheets (SDS) and labels compliant with OSHA’s revised Hazard Communication Standard (29 C.F.R. 1910.1200), effective June 1, 2015, and must train employees on these requirements. All documentation must align with DLA’s Master List of Technical and Quality Requirements, and the unit of issue is BT, equivalent to 15 mL. The contract is issued under SPE2DP-26-T-4354, with a response deadline of August 4, 2026, and is governed by federal procurement regulations including DLA packaging and hazardous material handling standards.
Pharmaceutical Preparation Manufacturing

POSTED

about 20 hours ago

DEADLINE

in 5 days
View Details
NAICS: 325412
New
DIBBS
DIBUCAINE OINTMENT
Solicitation # SPE2DP-26-T-4358
Dibucaine Ointment USP is a topical pharmaceutical product containing one percent dibucaine as the active ingredient, specifically formulated for rectal administration and external use only. It is supplied in a collapsible tube and a rectal applicator, with each unit of issue being a single package containing one ounce or 28 grams of the ointment. Storage requirements mandate a temperature range of 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit). The product is regulated by the FDA and must be marked in accordance with the latest edition of Medical Marking Standard No. 1, with a non-extendable shelf life of 36 months as a Type I (Code Q) item. Packaging must comply with MIL-STD-2073-1E, and government identification must be removed from any non-accepted supplies. The contract specifies a procurement quantity of two packages, to be delivered FOB destination within 20 days, with zero variance allowed in quantity. The item is identified by NSN 6505002999535 and NDC 00536-1211-95, supplied by The Harvard Drug Group, L.L.C. The solicitation number is SPE2DP-26-T-4358, with a response deadline of August 4, 2026, and the place of performance is Nellis AFB, NV. The contract includes adherence to DLA’s Master List of Technical and Quality Requirements, and buyers must submit referrals in EBS to confirm product compliance prior to award.
Pharmaceutical Preparation Manufacturing

POSTED

about 20 hours ago

DEADLINE

in 5 days
View Details